Elutia INC 8-K filings

Elutia Inc. received a notice from Nasdaq indicating its stock price has fallen below the minimum requirement for continued listing, triggering a compliance period.

Elutia Inc. has entered into a definitive agreement to sell its SimpliDerm business to Cellution Biologics Inc. for a total consideration of up to $11 million.

Elutia Inc. stockholders approved the expansion of its 2020 Incentive Award Plan and re-elected board members at the 2026 Annual Meeting.

Elutia Inc. announced it has regained full compliance with Nasdaq's minimum bid price and market value requirements, ensuring its continued listing.

Elutia Inc. announced preliminary fourth-quarter 2025 results, showcasing a 16% revenue increase, significant debt reduction, and progress on its NXT-41x antibiotic-eluting biomatrix program.

Elutia Inc. received a Nasdaq notice for non-compliance with minimum market value and bid price requirements, initiating a compliance period to avoid delisting.

Elutia Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Elutia Inc. announced its third quarter 2025 financial results, the $88 million sale of its BioEnvelope business, and plans to fully fund the development of its next-generation antibiotic-eluting biomatrix, NXT-41x.

Elutia Inc. announced the appointment of Guido J. Neels to its Board of Directors and Audit Committee, alongside the resignations of two existing directors.

Elutia Inc. announced the closing of its BioEnvelope business sale to Boston Scientific Corporation for $88 million in cash, enabling a focused strategy on its NXT-41x breast reconstruction platform.

Elutia Inc. announced the sale of its Cardiac Implantable Electronic Device (CIED) business, including its EluPro and CanGaroo bioenvelopes, to Boston Scientific Corporation for $88 million in cash, aiming to transform its balance sheet and fund its breast reconstruction pipeline.

Elutia Inc. has entered into a Fifth Amendment to its Credit Agreement, capitalizing accrued interest and fees into its senior secured term loan, increasing the principal balance to over $25 million.

Elutia Inc. reported robust Q2 2025 revenue growth for its EluPro product and progress in its next-generation biomatrix pipeline, despite overall flat net sales and increased operating losses.

Elutia Inc. announced that its stockholders approved the election of two Class II directors and ratified PricewaterhouseCoopers LLP as its independent registered public accounting firm at the annual meeting held on May 29, 2025.

Elutia reports strong first-quarter 2025 financial results, highlighted by an 84% sequential increase in EluPro sales and a new strategic partnership with Boston Scientific.

Elutia Inc. announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio following the conclusion of its distribution agreement with LeMaitre Vascular, Inc., expecting to drive top-line growth and gross margin improvement.

Elutia Inc. reports strong initial market uptake for EluPro, driving BioEnvelope sales up 18% and same-center sales up 65% following its commercialization.

Elutia Inc. has entered into a definitive agreement for a registered direct offering of common stock and prefunded warrants, expected to generate approximately $15 million in gross proceeds.

Elutia Inc. reports preliminary net sales for 2024, showing a slight overall decrease, with a notable decline in the cardiovascular segment.

Elutia Inc. announced its third quarter results, highlighting the first commercial use of EluPro and a 19% growth in SimpliDerm sales, while preparing for a full EluPro launch in 2025.

Elutia Inc. has amended its credit agreement, deferring principal repayments and extending interest payment options.

Elutia Inc. reports its second quarter 2024 results, highlighting the FDA clearance and production launch of EluPro, along with a strengthened financial position.

Elutia Inc. has entered into a definitive agreement for a registered direct offering of common stock and prefunded warrants, expected to generate approximately $13.26 million in gross proceeds.

Elutia Inc. has announced FDA clearance for its EluPro antibiotic-eluting bioenvelope, designed to prevent post-operative complications in implantable devices.

Elutia Inc. successfully held its annual meeting of stockholders on June 6, 2024, electing two Class I directors and ratifying PricewaterhouseCoopers LLP as its independent auditor.

Elutia Inc. announced a 55% increase in SimpliDerm sales and anticipates FDA clearance for CanGarooRM in the second quarter of 2024.

Elutia Inc. has modified its credit agreement to lower the minimum revenue requirement for its loan facility, effective from the first fiscal quarter of 2024.

Elutia Inc. announced its fourth quarter and full year 2023 financial results, highlighting strong revenue growth in its proprietary product lines and anticipating a key regulatory decision for its CanGarooRM product in the first half of 2024.

Elutia Inc. has repriced and restructured certain outstanding equity incentives and granted additional equity incentives to employees, including the CEO and other executive officers.

Elutia Inc. has amended its royalty agreement with Ligand Pharmaceuticals, increasing minimum annual and quarterly payments while waiving a $5 million milestone payment.